English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Some errors have been noted in the abovementioned paper subsequent to publication and so the following corrections should be highlighted. On page 1091 under the heading Treatment Patterns, the sentence ‘‘Overall, the mean duration of treatment was 152.6 days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment’’ should read ‘‘Overall, the mean duration of treatment was 151.2 days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment.’’ It should be clarified that 152.6 days was the mean duration of the double-blind treatment phase. On page 1092 in Fig. 3, the p value for the FAS group should read p = 0.0005, and not p\0.0001. On page 1095 under the heading Safety/ Tolerability, the sentence ‘‘The most common adverse event was peripheral edema, which was reported in 17.8% of OLM/AML patients and 18.1% of PER/AML recipients’’ should read ‘‘The most common adverse event was peripheral edema, which was reported in 18.4% of OLM/ AML patients and 17.8% of PER/AML recipients.’’ On page 1095 in Table 2, the values in the row showing the frequencies of peripheral edema which are currently: 43 (17.8) in the OLM/AML column, 88 (18.1) in the PER/AML column, and 45 (18.4) in the total column; should read: 45 (18.4), 43 (17.8), and 88 (18.1), respectively. The online version of the original article can be found under doi:10.1007/s12325-013-0076-6.

advances in therapy

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension